



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

FRENKEN ET AL

Serial No. 09/626,242

Group Art Unit: 1639

Filed: September 27, 2000

Examiner: P. Ponnaluri

For: METHOD FOR PRODUCING
ANTIBODY FRAGMENTS

07/30/2003 LWONDIM1 00000076 500310 09626242

01 FC:1814 110.00 DA

TERMINAL DISCLAIMER

(by Attorney)

Re: Double-Patenting Rejection

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

The undersigned petitioner, an attorney of record, is hereby acting for the under-named entities which are the 100% owner of all rights, title and interests in and to the above-noted application as shown by the **Assignment recorded on October 19, 2000 on Reel 011248, Frame 0103** and hereby disclaims the terminal part of the statutory term of any patent granted on the subject application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 145 to 156 and 173, as presently shortened (if at all) by any terminal disclaimer of the earlier granted United States **Patent No 6,399,763** to which said entity also has legal title. Petitioner hereby reserves the right to extend the term of the patent, which issues on this application, for regulatory delay or otherwise as the law allows. Petitioner hereby agrees that any patent so granted on the subject application shall be enforceable only for and during such period that it and the above-noted patent are commonly owned. This agreement runs with any

~~07/30/2003 LWONDIM1 00000076 500310 09626242~~

~~01 FC:1251 110.00 DA~~

TECH CENTER 1600/2900

JUL 31 2003

RECEIVED

17

FRENKEN ET AL
Serial No. 09/626,242

patent granted on the subject application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, petitioner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the above-noted patent, as presently shortened by any terminal disclaimer, of the above-listed patent in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is otherwise terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

The required Terminal Disclaimer fee (\$110.00) should be charged to Deposit Account No. 50-0310.

UNILEVER PATENT HOLDINGS BV

By 

Attorney of record: Paul N. Kokulis
Registration No. 16,773

Date: July 28, 2003